Novo Nordisk A/S : Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity trial with liraglutide 3 mg

 Novo Nordisk A/S : Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in
                 phase 3a obesity trial with liraglutide 3 mg

Company announcement No 39 2013

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE
HUG#1704259
 
Press spacebar to pause and continue. Press esc to stop.